Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards granted by its Compensation Committee on October 6, 2025 to 21 new employees under the 2024 Inducement Plan.
The grants consist of 135,100 non‑qualified stock options and 70,775 restricted stock units (RSUs). Each option has an exercise price of $30.94, equal to Vera Therapeutics’ closing price on October 6, 2025. Options vest over four years with 25% after one year and monthly vesting over the following 36 months. RSUs vest 25% on each anniversary beginning November 20, 2025, over four years. Awards are subject to the Inducement Plan and individual award agreements and to continued service through vesting dates.
Vera Therapeutics (Nasdaq: VERA) ha annunciato premi azionari di incentivazione concessi dal suo Compensation Committee il 6 ottobre 2025 a 21 nuovi dipendenti ai sensi del piano di induzione 2024. Le assegnazioni consistono in 135.100 stock option non qualificate e 70.775 unità di azioni restritte (RSU). Ogni opzione ha un prezzo di esercizio di 30,94 dollari, pari al prezzo di chiusura di Vera Therapeutics il 6 ottobre 2025. Le opzioni maturano in quattro anni con il 25% dopo un anno e con maturazione mensile nei 36 mesi successivi. Le RSU maturano al 25% a ogni anniversario a partire dal 20 novembre 2025, nel corso di quattro anni. Le assegnazioni sono soggette al piano di induzione e agli accordi individuali di assegnazione e al proseguimento del servizio fino alle date di maturazione.
Vera Therapeutics (Nasdaq: VERA) anunció premios de acciones de inducción concedidos por su Comité de Compensación el 6 de octubre de 2025 a 21 nuevos empleados bajo el Plan de Inducción de 2024. Las adjudicaciones consisten en 135.100 opciones de acciones no calificadas y 70.775 unidades de acciones restringidas (RSU). Cada opción tiene un precio de ejercicio de $30.94, igual al cierre de Vera Therapeutics el 6 de octubre de 2025. Las opciones se consolidan/encuentran en vesting durante cuatro años con un 25% después de un año y vesting mensual durante los siguientes 36 meses. Las RSU vencen 25% en cada aniversario a partir del 20 de noviembre de 2025, durante cuatro años. Las adjudicaciones están sujetas al Plan de Inducción y a los acuerdos de adjudicación individuales y al mantenimiento del servicio hasta las fechas de consolidación.
Vera Therapeutics (나스닥: VERA)는 2025년 10월 6일 보상위원회가 2024년 유인 계획에 따라 21명의 신입 직원에게 부여한 유인 주식 보상에 대해 발표했습니다. 부여 내용은 135,100주의 비자격 주식매입선택권과 70,775주의 제한주식단위(RSU)로 구성됩니다. 각 옵션의 행사가격은 30.94달러로 2025년 10월 6일 Vera Therapeutics의 종가와 동일합니다. 옵션은 4년에 걸쳐 vest되며 1년 후 25%, 이후 36개월 동안 매월 vesting됩니다. RSU는 2025년 11월 20일부터 매년 25%씩 vest되며, 총 4년에 걸쳐 vest됩니다. 보상은 Inducement Plan 및 개별 상여계약 및 vesting일자까지의 지속적인 서비스에 따라 적용됩니다.
Vera Therapeutics (Nasdaq: VERA) a annoncé des récompenses d'induction accordées par son Comité de rémunération le 6 octobre 2025 à 21 nouveaux employés dans le cadre du Plan d'induction 2024. Les attributions se composent de 135 100 options d'achat d'actions non qualifiées et de 70 775 unités d'actions restreintes (RSU). Chaque option a un prix d'exercice de 30,94 $, égal au cours de clôture de Vera Therapeutics le 6 octobre 2025. Les options s'acquièrent sur quatre ans avec 25 % après un an et une acquisition mensuelle au cours des 36 mois suivants. Les RSU s'acquièrent à raison de 25 % à chaque anniversaire à partir du 20 novembre 2025, sur quatre ans. Les récompenses sont soumises au Plan d'induction et aux accords individuels de récompense, ainsi qu'à la poursuite du service jusqu'aux dates d'acquisition.
Vera Therapeutics (Nasdaq: VERA) gab Anreize-Aktienzuteilungen bekannt, die am 6. Oktober 2025 von ihrem Vergütungsausschuss an 21 neue Mitarbeiter im Rahmen des 2024 Inducement Plans gewährt wurden. Die Zuteilungen bestehen aus 135.100 nicht qualifizierten Aktienoptionen und 70.775 restriktiven Aktien-Einheiten (RSUs). Jede Option hat einen Ausübungspreis von 30,94 $, entsprechend dem Schlusskurs von Vera Therapeutics am 6. Oktober 2025. Optionen vesten über vier Jahre mit 25 % nach einem Jahr und monatlicher Vesting über die folgenden 36 Monate. RSUs vesten 25 % an jedem Jahrestag ab dem 20. November 2025, über vier Jahre. Die Zuteilungen unterliegen dem Inducement Plan und individuellen Zuteilungsvereinbarungen sowie der fortgesetzten Diensterfüllung bis zu den Vesting-Terminen.
أعلنت Vera Therapeutics (ناسداك: VERA) عن جوائز أسهم حوافز قُدمت من لجنة التعويض لديها في 6 أكتوبر 2025 لـ21 موظفًا جديدًا بموجب خطة الحوافز لعام 2024. وتتكون المنح من 135,100 خيار أسهم غير مؤهلة و70,775 وحدة أسهم مقيدة (RSU). كل خيار لديه سعر ممارسة قدره 30.94 دولارًا، وهو يساوي سعر إغلاق Vera Therapeutics في 6 أكتوبر 2025. تتراكم الخيارات خلال أربع سنوات بنسبة 25% بعد سنة واحدة وبالتسوية الشهرية خلال الـ36 شهرًا التالية. وتترك RSU عند 25% في كل ذكرى سنوية ابتداءً من 20 نوفمبر 2025، على مدى أربع سنوات. تكون الجوائز خاضعة لخطة inducement وللاتفاقات الفردية للجوائز ولينبغي استمرار الخدمة حتى تواريخ الاستحقاق.
Vera Therapeutics（纳斯达克股票代码：VERA）于2025年10月6日宣布其薪酬委员会在2024年诱导计划下，向21名新员工授予的诱导性股票奖励。此次授予包括135,100份非合格股票期权和70,775份受限股票单位（RSU）。每份期权的行使价为30.94美元，等于2025年10月6日的收盘价。期权在四年内分阶段归属，第一年归属25%，随后的36个月内按月归属。RSU自2025年11月20日起每周年归属25%，共四年完成归属。奖励受诱导计划和个人奖励协议的约束，并须在归属日期前持续任职。
Positive
None.
Negative
None.
BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 135,100 shares of Class A common stock and restricted stock units (RSUs) underlying 70,775 shares of Class A common stock to twenty-one (21) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on October 6, 2025 has an exercise price per share equal to $30.94, Vera Therapeutics’ closing trading price on October 6, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of November 20, 2025, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
AboutVera Therapeutics Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. In addition, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera Therapeutics also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera Therapeutics retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
